| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6346532 | APGDI | Amide derivatives or salts thereof |
Mar, 2022
(1 year, 6 months ago) | |
| US7342117 | APGDI | α-form or β-form crystal of acetanilide derivative |
Nov, 2023
(a month from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6346532 (Pediatric) | APGDI | Amide derivatives or salts thereof |
Sep, 2022
(1 year, 1 day ago) | |
| US7982049 | APGDI | α-form or β-form crystal of acetanilide derivative |
Nov, 2023
(a month from now) | |
| US8835474 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Nov, 2023
(a month from now) | |
| USRE44872 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Nov, 2023
(a month from now) | |
|
US7342117 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(7 months from now) | |
|
USRE44872 (Pediatric) | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
May, 2024
(7 months from now) | |
|
US8835474 (Pediatric) | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
May, 2024
(7 months from now) | |
|
US7982049 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(7 months from now) | |
| US8772315 | APGDI | Pharmaceutical composition for treating overactive bladder |
Oct, 2028
(5 years from now) | |
|
US8772315 (Pediatric) | APGDI | Pharmaceutical composition for treating overactive bladder |
Apr, 2029
(5 years from now) | |
| US10842780 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(6 years from now) | |
| US11707451 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(6 years from now) | |
|
US10842780 (Pediatric) | APGDI | Pharmaceutical composition for modified release |
Mar, 2030
(6 years from now) | |
|
US11707451 (Pediatric) | APGDI | Pharmaceutical composition for modified release |
Mar, 2030
(6 years from now) | |
Myrbetriq is owned by Apgdi.
Myrbetriq contains Mirabegron.
Myrbetriq has a total of 16 drug patents out of which 2 drug patents have expired.
Expired drug patents of Myrbetriq are:
- US6346532*PED
- US6346532
Myrbetriq was authorised for market use on 28 June, 2012.
Myrbetriq is available in tablet, extended release;oral dosage forms.
Myrbetriq can be used as use in combination with the muscarinic antagonist solifenacin succinate for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency, administration of an extended release tablet for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency; administration of an extended release tablet for the treatment of neurogenic detrusor overactivity (ndo) in pediatric patients aged 3 years and older and weighing 35 kg or more, for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency, administration of an extended release tablet for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
The generics of Myrbetriq are possible to be released after 28 March, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication (I) | Mar 25, 2024 |
| Pediatric Exclusivity (PED) | Sep 25, 2024 |
Drugs and Companies using MIRABEGRON ingredient
Market Authorisation Date: 28 June, 2012
Treatment: For the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency; Use in combination with the muscarinic antagonist solifenacin succinate for th...
Dosage: TABLET, EXTENDED RELEASE;ORAL
MYRBETRIQ family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic